Salubris refiles for Hong Kong IPO as generics lose steam
The producer of cardiovascular drugs is accelerating its shift towards innovative pharmaceuticals, under pressure from price cuts and expiring patents Key Takeaways: Salubris built its early success on generics, but…
BRIEF: Simcere Pharma profit surges in 2025
Innovative drugmaker Simcere Pharmaceutical Group Ltd. (2096.HK) said on Wednesday it expects to report a 2025 profit of between 1.3 billion yuan ($189 million) and 1.4 billion yuan, up 80.1%…
CSPC feels the pain from sweeping cuts in drug prices
The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…
FAST NEWS: SSY Group’s profit dips in nine months to September
The Latest: Medical products maker SSY Group Ltd. (2005.HK) reported on Friday its net profit for the first three quarter of this year fell 2.8% year-on-year to HK$919 million ($118 million). Looking…
FAST NEWS: Viva Biotech completes Langhua Pharma buyout
The latest: Viva Biotech Holdings (1873.HK) announced Thursday that the acquisition of 20% of Langhua Pharmaceutical by its Weizongchen Pharmaceutical subsidiary for 640 million yuan ($87.6 million) has been completed. Looking…
FAST NEWS: Ascletis Pharma’s loss narrows as core product sales surge
The latest: Ascletis Pharma Inc. (1672.HK) announced Tuesday its net loss narrowed sharply in the first half of this year to 16.56 million yuan ($2.3 million) from an 88 million…
FAST NEWS: Simcere’s revenue jumps on rising innovative drug sales
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) said on Thursday it expects to report its revenue grew between 24% and 26.3% to between 3.35 billion yuan ($468 million) and 3.41 billion yuan in…
Recent Articles
RELATED ARTICLES
-
CSPC Innovation pursues Hong Kong IPO as parent profits shrink
300765.SHE -
BRIEF: Capital Securities gets regulatory nod, refiles for Hong Kong IPO
601136.SHG
-
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
-
Drug spin-off trend gains traction with IPO by Hengrui offshoot
1276.HK600276.SHG
- Precision-drug maker Impact Therapeutics ignites IPO frenzy
-
Alebund soars in Hong Kong debut on kidney treatment hopes
9637.HK
